eISSN 2508-3589
pISSN 2508-1926

Table. 2.

Table. 2.

Before and after treatment comparison of BCVA, CMT, and IOP according to macular perfusion status and treatment type

Feature Before treatment After treatment p-value *
BCVA (logMAR)
Non-perfusion
Group A 0.876 ± 0.612 0.438 ± 0.236 0.008
Group B 1.481 ± 0.406 0.791 ± 0.387 0.006
Group C 0.732 ± 0.559 0.596 ± 0.661 0.016
Perfusion
Group A 0.603 ± 0.369 0.423 ± 0.339 0.066
Group B 0.839 ± 0.544 0.625 ± 0.717 0.173
Group C 0.522 ± 0.228 0.440 ± 0.299 0.055
CMT (μm)
Non-perfusion
Group A 673.4 ± 163.2 236.2 ± 32.6 0.005
Group B 689.2 ± 244.2 276.7 ± 157.7 0.001
Group C 533.8 ± 194.6 269.4 ± 105.4 <0.0001
Perfusion
Group A 589.8 ± 173.7 274.8 ± 110.0 0.028
Group B 661.6 ± 106.7 375.1 ± 171.8 0.028
Group C 472.3 ± 186.4 267.3 ± 123.2 <0.0001
IOP (mmHg)
Non-perfusion
Group A 9.7 ± 2.3 12.0 ± 2.1 0.014
Group B 9.5 ± 2.8 10.1 ± 2.3 0.384
Group C 9.6 ± 2.3 10.3 ± 2.8 0.058
Perfusion
Group A 11.0 ± 2.5 10.2 ± 1.5 0.257
Group B 10.3 ± 2.7 12.7 ± 4.0 0.071
Group C 9.7 ± 2.5 10.8 ± 3.7 0.125

Values are presented as mean ± standard deviation. Group A refers to the dexamethasone implant injection arm. Group B refers to the bevacizumab to dexamethasone implant injection arm.

Group C refers to the bevacizumab injection arm.

BCVA = best-corrected visual acuity; logMAR = logarithm of minimal angle of resolution; CMT = central macular thickness; IOP = intraocular pressure.

*
p-value for two-group comparison by the paired t-test.

J Retin 2020;5:135-42 https://doi.org/10.21561/jor.2020.5.2.135
© 2020 J Retin